Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP (A-CHOP-14)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00725231
Recruitment Status : Unknown
Verified May 2012 by Prof. Dr. Lorenz Trümper, University of Göttingen.
Recruitment status was:  Recruiting
First Posted : July 30, 2008
Last Update Posted : May 7, 2012
German High-Grade Non-Hodgkin's Lymphoma Study Group
Nordic Lymphoma Group
Information provided by (Responsible Party):
Prof. Dr. Lorenz Trümper, University of Göttingen

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : March 2014
  Estimated Study Completion Date : March 2014